60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Short Interest Update

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) was the recipient of a significant decline in short interest in October. As of October 15th, there was short interest totalling 16,500 shares, a decline of 47.3% from the September 30th total of 31,300 shares. Based on an average daily trading volume, of 421,900 shares, the short-interest ratio is currently 0.0 days. Currently, 1.0% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, September 13th.

60 Degrees Pharmaceuticals Price Performance

SXTP stock traded down $0.05 on Friday, hitting $0.81. 45,946 shares of the company were exchanged, compared to its average volume of 258,209. 60 Degrees Pharmaceuticals has a twelve month low of $0.80 and a twelve month high of $18.36. The business’s fifty day moving average is $1.29 and its two-hundred day moving average is $0.65. The stock has a market capitalization of $1.51 million, a price-to-earnings ratio of 8.85 and a beta of 4.62.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($4.23) EPS for the quarter, missing the consensus estimate of ($2.79) by ($1.44). The company had revenue of $0.13 million for the quarter, compared to analysts’ expectations of $0.11 million. Equities research analysts expect that 60 Degrees Pharmaceuticals will post -3.17 earnings per share for the current year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.